Communiqués Lundbeck Nasdaq Copenhagen

Actions

LUN

DK0061804697

Produits pharmaceutiques

PEA

Temps réel estimé Cboe Europe 11:19:18 13/10/2026			Varia. 5j.	Varia. 1 janv.
45,20 ^DKK	+2,73 %		+4,40 %	+24,59 %

06/10	H. Lundbeck A/S présente les données de phase Ib de Lu AF28996 dans la maladie de Parkinson avancée, alors que l’essai de phase II débute	CI
06/10	Lundbeck présente des données positives de phase Ib pour un traitement contre la maladie de Parkinson	FW

Communiqués

06/10	Lundbeck presents Phase Ib data for Lu AF28996 in advanced Parkinson's disease, as Phase II trial begins	AQ
02/10	Lundbeck to showcase progress across its movement disorders pipeline with data in multiple system atrophy and Parkinson's disease at MDS® 2026	AQ
01/10	Lundbeck announces headline results from Phase IV THRIVE trial evaluating VYEPTI® (eptinezumab) following inadequate response to prior CGRP-targeting preventive therapy	AQ
28/09	Lars Bang, Executive Vice President, Product Development & Supply, has passed away	AQ
25/09	Lundbeck to establish global innovation hub in Greater Boston and relocate US headquarters	AQ
21/09	H Lundbeck A/S : Correction - Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties	PU
17/09	Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties	AQ
16/09	Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in Japan for the prevention of migraine attacks	AQ
15/09	Lundbeck announces last patient randomized in DEEp SEA, a Phase III trial of bexicaserin in Dravet syndrome	AQ
11/09	The U.S. FDA grants orphan drug designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for treatment of endogenous Cushing's syndrome	AQ
03/09	Lundbeck to highlight mechanistic insights on bexicaserin's dual mode of action at the European Epilepsy Congress	AQ
24/08	European Commission grants orphan designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for Cushing's syndrome of endogenous origin	AQ
19/08	Lundbeckfond Invest A/S launches voluntary exchange offer for A-shares in H. Lundbeck A/S	AQ
19/08	Strong growth from Vyepti[®] and focused commercial execution drive total revenue growth of +16% CER (+13% CER underlying) in H1 2026	AQ
23/07	Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy	AQ
20/07	Lundbeck announces last patient randomized in DEEp OCEAN, a large Phase III trial in developmental and epileptic encephalopathies (DEEs)	AQ
24/06	Tarek Samad appointed EVP, Head of Research & Development at Lundbeck	AQ
24/06	Lundbeck presents new Vyepti® (eptinezumab) and bocunebart migraine portfolio data at EAN 2026	AQ
14/06	Lundbeck presents new Phase II asedebart data in Cushing's disease at ENDO 2026	AQ
10/06	Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026	AQ
04/06	Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress	AQ
03/06	Lundbeck Partners with Cradle to Discover and Optimize Brain Disorder Treatments	AQ
26/05	Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in South Korea for the preventive treatment of migraine	AQ
19/05	H Lundbeck A/S : Transcript (Transcript)	PU
18/05	Lundbeck receives orphan drug designation in Japan for asedebart for the treatment of patients with congenital adrenal hyperplasia and Cushing's disease	AQ